Protocol Ledger

NCT07741448 · Phase II · RECRUITING

Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

Interventional Phase II clinical trial protocol NCT07741448 sponsored by Zhiquan Hu in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-15 Enrollment: 54 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07741448
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)54 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07741448
Protocol FieldVerified Registry Value
NCT IdentifierNCT07741448
Consolidated Lead SponsorZhiquan Hu
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment54 participants (ESTIMATED)
Registered Start Date2026-08-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07741448
Hospital Research SiteLocationSite Profile
Renmin Hospital of Wuhan UniversityWuhan, ChinaOpen Hospital Dossier ->
Zhongnan Hospital of Wuhan UniversityWuhan, ChinaOpen Hospital Dossier ->
Hubei Cancer HospitalWuhan, ChinaOpen Hospital Dossier ->
Xiangyang Central HospitalXiangyang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI